ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Industrials / IDXG / options
JBDI (46) BHST (34) RML (47) STKE (44) ⌘ Pro Terminal →

Interpace Biosciences Inc. (IDXG) Options Positioning, Max Pain & Unusual Sweeps

$5.44 -2.68% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $5.40

Interpace Biosciences Inc. (IDXG) carries a Roarable Rating of C (Hold) with 63/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $22.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on IDXG Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is IDXG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Interpace Biosciences Inc. (NASDAQ: IDXG) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $5.44 (-2.68% 1D, market cap $22.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 15/20. Across 486 tracked Industrials issuers, IDXG ranks #95 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does IDXG compare to JBDI and BHST in the Industrials sector?
▼

Within the Industrials sector (Diversified Equities), IDXG carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of 16.2%. By comparison, JBDI (JBDI Holdings Limited) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $22.5M) and BHST (BioHarvest Sciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, IDXG leads on earnings multiple (N/A) while IDXG leads on capital efficiency (16.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for IDXG?
▼

Per IDXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001054102), Interpace Biosciences Inc. generated $38.7M in revenue (-17.5% YoY), $24.6M in net income, and $5.5M in free cash flow against $33.8M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $5.40 (-0.67%)🧬 Cannibal Buyback (-2.08% YoY Shares)⚙️ Cash Engine: 9/20 (D) • 14.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 63/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.9% avg 90D alpha vs SPY • 54.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510063
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B
Cash (9)Whales (10)SEC (13)Macro (16)CEO (15)
Each axis scored 0–20
12M PRICE TARGET CONE+2.2% Base Target
$8 Bull$6 Base$4 Bear
📬 FREE IDXG RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IDXG)Realized 20D OHLCV Swing Band: ±11.3%
Deterministic 5-Pillar Attribution (63/100 Composite)
🔍 WHY IDXG SCORES 63/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+16/20 pts (25% of score)

FRED Regime × Technicals: 66% of 52W Range • RSI-14 at 49.8 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+15/20 pts (24% of score)

SEC Form 4 / 13F Thermometer: 75% Net Buy • Cannibal Buyback (-2.08% YoY Shares)

▼ #1 Drag / Risk Factor: Cash Engine Quality9/20 pts (-11 pt drag)

Capital intensity & 10.5% operating margin leave 11 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
71
Grade B$5.90-10.2% Next Q
Q2 (-2Q)
68
Grade B-$5.30+3.8% Next Q
Q3 (-1Q)
66
Grade B-$5.50-1.1% Next Q
Current
63
Grade C$5.44+0.9% Hist 90D α
Trajectory: B (71) → C (63)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the IDXG Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 63/100 (C) score, IDXG faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 59.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($5.87) or 200D SMA ($2.79) invalidates the momentum regime and cuts Target Base ($5.56) toward Bear Floor ($4.34).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IDXG• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “IDXG Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 63%NO 37%Trade / Inspect Odds →
CALL VS. PUT WHALE SHARE
— (No Active Options Snapshot)
Put/Call Ratio: — (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
— (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
±11.3%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (IDXG)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for IDXG.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating IDXG & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on IDXG
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
IDXG // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +172.00%▼ DESCENDING CHANNEL
2026-11-03O $5.72H $5.72L $5.44C $5.44VOL 502
RES: $6.27SUP: $0.84SMA50: $5.87SMA200: $2.79
$8.25$6.37$4.48$2.60$0.71RES $6.27SUP $0.84$5.442026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IDXG Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IDXG Butterfly Map → + Track IDXG →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-11.1%/yr Implied 5Y Growth

vs. -17.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on IDXG today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IDXG. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for IDXG today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IDXG)

Industrials Rank #95 of 486 ⚔️ JBDI vs IDXG Full Matrix →

1. Head-to-Head Industrials Peer Comparison (IDXG vs. JBDI, BHST, RML, STKE)

Industry: Diversified Equities (43 Tracked Issuers)

Across 486 tracked Industrials securities in the Roarable RQD universe, Interpace Biosciences Inc. (IDXG) ranks #95 by composite RQD confidence (63/100, grade C) and #430 by equity capitalization ($22.7M). Within this direct 5-issuer industry benchmark cohort, IDXG leads on earnings valuation at N/A trailing P/E, while IDXG leads on capital efficiency and profitability with 16.2% ROIC and 62.3% gross margin. IDXG currently leads its immediate peer cohort in composite quantitative strength at 63/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
IDXG ACTIVE
Interpace Biosciences Inc.
C 63/100 — 62.3% 16.2% -2.68% $22.7M Benchmark Subject
JBDI
JBDI Holdings Limited
D 46/100 — 49.9% — +4.66% $22.5M /jbdi-vs-idxg →
BHST
BioHarvest Sciences Inc.
E 34/100 — 59.3% -35.0% -5.42% $37.6M /bhst-vs-idxg →
RML
Resolution Minerals Ltd
D 47/100 — — — -2.08% $43.0M /rml-vs-idxg →
STKE
Sol Strategies Inc.
D 44/100 — — — -5.69% $48.6M /stke-vs-idxg →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001054102 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Interpace Biosciences Inc. (IDXG) reported GAAP revenue of $38.7M (-17.5% vs. FY2024 revenue of $46.9M , and -3.3% cumulative change since FY2023) , GAAP net income of $24.6M, operating cash flow of $5.8M, and free cash flow of $5.5M (+45.2% YoY). On the balance sheet, IDXG closed FY2025 with $33.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $38.7M $24.6M $5.8M $5.5M $33.8M —
FY2024 (FY) 2024-12-31 $46.9M $6.7M $4.6M $3.8M $14.8M —
FY2023 (FY) 2023-12-31 $40.0M $2.0M $3.8M $3.8M — —

3. IDXG Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IDXG stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Interpace Biosciences Inc. (NASDAQ: IDXG) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 63/100 at a spot price of $5.44 (-2.68% 1D, market cap $22.7M). Pillar breakdown: Fundamental Cash Engine 9/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 15/20. Across 486 tracked Industrials issuers, IDXG ranks #95 in composite RQD confidence.

How does IDXG compare to JBDI and BHST in the Industrials sector?

Within the Industrials sector (Diversified Equities), IDXG carries a Roarable C (63/100 RQD), trailing P/E of N/A, gross margin of 62.3%, and ROIC of 16.2%. By comparison, JBDI (JBDI Holdings Limited) holds a D grade (46/100 RQD, P/E N/A, ROIC —, cap $22.5M) and BHST (BioHarvest Sciences Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $37.6M). Among the 5-stock peer group, IDXG leads on earnings multiple (N/A) while IDXG leads on capital efficiency (16.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IDXG?

Per IDXG's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001054102), Interpace Biosciences Inc. generated $38.7M in revenue (-17.5% YoY), $24.6M in net income, and $5.5M in free cash flow against $33.8M in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IDXG trading relative to its 50-day, 200-day, and 52-week technical levels?

IDXG last traded at $5.44 (-2.68% on volume of 204 shares), positioning the stock -7.33% below its 50-day simple moving average ($5.87) and +94.98% above its 200-day simple moving average ($2.79). Across its 52-week range of $0.81 to $7.80, IDXG sits at the 66.2% percentile with a 14-day RSI of 49.8 (NEUTRAL RANGE) and an implied next-earnings move of ±11.3% ($4.83 to $6.05).

Direct Sub-Reports: IDXG RQD Cockpit IDXG 12M Forecast IDXG Earnings & Move IDXG Dividends & DRIP IDXG Insiders & 13F IDXG Whale Options IDXG Profit Sankey IDXG News & Why
ROARABLE RATING BRIEF • RQD 63/100 (C) ✓ SEC XBRL & RQD VERIFIED

IDXG — Interpace Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Interpace Biosciences Inc. (IDXG) earns a live Roarable RQD composite score of 63/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $5.44 (-2.68% 1D, market capitalization $22.7M).

  • Fundamental Cash Engine (9/20): Anchored by return on invested capital (ROIC) of 16.2%, gross margin of 62.3%, operating margin of 10.5%, and free cash flow yield of 23.60%.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (15/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (16/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Interpace Biosciences Inc. Is a NASDAQ-listed issuer classified under the Industrials sector and Diversified Equities industry,. Gross margin is reported at 62.3% and operating margin at 10.5% per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Interpace Biosciences Inc. (IDXG) reported $38.7M in annual revenue (up from $46.9M in FY2024, -17.5% YoY) and $24.6M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($40.0M revenue, $2.0M net income) through FY2025, IDXG scaled operating cash flow to $5.8M and free cash flow to $5.5M, backed by $33.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 63/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 23.60% and institutional whale pillar of 10/20. With Fundamental Cash Engine at 9/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $0.81 – $7.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh current valuation and 4.7x EV/EBITDA against 10.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The sector and industry labels alone do not establish correlations.

  • Key Question #1: Can IDXG sustain or expand its 10.5% operating margin and 16.2% ROIC against Diversified Equities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $38.7M and free cash flow of $5.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is IDXG's equity valuation to Industrials capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

IDXG Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Interpace Biosciences Inc. (IDXG) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to IDXG Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

IDXG Bull vs. Bear Conversation Board — What's Your Call at $5.44?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON IDXG 🐻 33% BEARISH CONVICTION
1. Pick Your Side on IDXG:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $6.76 (+20.9%)
📌 Pinned Debate

The stock trades at an EV/EBITDA of 4.7 with a reported FCF yield of 23.6% and ROIC of 16.2%, while the Roarable RQD rating shows insid

The stock trades at an EV/EBITDA of 4.7 with a reported FCF yield of 23.6% and ROIC of 16.2%, while the Roarable RQD rating shows insider conviction of 15 of 20.. When you look under the hood at IDXG, Fundamental Cash Engine is 9/20 with 62.3% gross margins and 16.2% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (10/20) has been quietly accumulating below $7.80. My 12M target is $6.76.

CapAlloc_Nerd 🐂 BULL

@DeepValue_CFA Agree on the RQD 63/100 quality, though with 1.0 beta I'm scaling in with half-size at $5.59 and keeping dry powder in case we test $5.20.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $4.19 (-25.0%)
Spot @ $5.59

Reported revenue fell from $46.9M in FY 2024 to $38.7M in FY 2025, and a 3.1M share offering is being priced amid Nasdaq listing plans.

Careful chasing IDXG at $5.59. Reported revenue fell from $46.9M in FY 2024 to $38.7M in FY 2025, and a 3.1M share offering is being priced amid Nasdaq listing plans.. Gross margin is 62.3%, but operating margin is 10.5%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $4.19 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%